Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov
Medical Student, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA
Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA
O’Donnell Brain Institute, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA
Highlights
- •Thirty-three trials of GLP-1 receptor agonists for substance use disorders identified.
- •Most trials are focused on alcohol and nicotine with heterogenous outcomes.
- •Few trials for stimulant use disorders, and none for cannabis use disorder.
Abstract
Background
Substance use disorders (SUDs) are widely prevalent and associated with high morbidity and mortality. Current treatments have limited efficacy and there are no United States Food and Drug Administration (FDA)-approved treatments for several SUDs (such as methamphetamine, cocaine, and cannabis use disorders). Emerging evidence suggests glucagon-like peptide 1 receptor agonists (GLP-1RAs) may improve outcomes related to SUD. Therefore, a systematic survey of ongoing clinical trials that are evaluating the effects of GLP-1RAs for SUDs is warranted.
Methods
We searched ClinicalTrials.gov from inception to July 2, 2025 (preregistered at: https://osf.io/x58ne/). Inclusion required a GLP-1RA intervention targeting SUDs and outcomes regarding substance use (e.g., urine toxicology, Timeline Follow-Back, craving). Trials excluding individuals with SUDs were excluded.
Results
Of 192 records, 33 met criteria: alcohol use disorder (n = 15), nicotine/tobacco (n = 9), cocaine (n = 4), opioid (n = 4), methamphetamine (n = 1), and none for cannabis. Agents studied included semaglutide (n = 15), exenatide (n = 8), tirzepatide (n = 6), liraglutide (n = 2), dulaglutide (n = 1), and pemvidutide (n = 1). Outcomes and designs were heterogeneous and often mixed self-report with objective indices. Most studies used older GLP-1RAs, focused mainly on alcohol or nicotine/tobacco use disorder, and used a range of outcome measures relying on self-reported and objective measures of substance use.
Conclusions
While GLP-1RAs may represent a paradigm shift for treating SUD, current trials have focused on alcohol and nicotine/tobacco use disorders, with notable gaps for methamphetamine and cannabis use disorders. Trials testing next-generation GLP-1RAs with FDA recommended endpoints are needed to define efficacy and safety across SUDs.
Article notes
Untitled section
Received 2025 Sep 29; Revised 2026 Jan 5; Accepted 2026 Jan 26; Collection date 2026 Jun.
1.Introduction
Substance use disorders (SUDs) are associated with substantial morbidity and mortality due, in part, to overdoses, alcohol related diseases, infectious disease, suicide, and accidental injuries (Perry et al., 2022). Prevalence rates of certain SUDs, such as methamphetamine use disorder, have increased markedly in the past decade which is further complicated by polysubstance use and contamination of supplies with fentanyl (Han et al., 2021). While several pharmacologic agents have been approved by the United States (US) Food and Drug Administration (FDA) for alcohol use disorder (AUD; naltrexone, acamprosate, disulfiram) (McPheeters et al., 2023), tobacco/nicotine use disorder (nicotine replacement therapy, varenicline, bupropion) (Selby & Zawertailo, 2022), and opioid use disorder (OUD; methadone, buprenorphine) (Bell & Strang, 2020), there are no FDA approved treatments for methamphetamine, cocaine, and cannabis use disorder (Clinical Guideline Committee (CGC) Members, 2024; Nielsen et al., 2019). Therefore, there is a significant unmet need for developing novel treatments for SUDs.
Glucagon-like peptide-1 receptor (GLP-1R) agonists (GLP-1RAs), first approved by the FDA in 2005 for the treatment of type II diabetes and recently for chronic weight management, have gained attention for their potential role in the treatment of SUD. These medications activate GLP-1R throughout the pancreas and several other tissues and exert systemic effects, including those in the central nervous system (Collins & Costello, 2025). Furthermore, the GLP-1Rs are expressed in reward-related brain regions (Bruns Vi et al., 2024) and a recent study of individuals with obesity found changes in reward-related brain regions in response to food cues with the use of GLP-1RAs (Martin et al., 2025). In preclinical studies, use of GLP-1RAs is associated with reduced intake and reinforcing properties of addictive substances (Edvardsson et al., 2025, Marquez-Meneses et al., 2025); thereby, supporting their therapeutic potential for SUDs (Volkow & Xu, 2025).
Recent reports based on data from electronic health records provide further evidence for potential therapeutic utility of GLP-1RAs for SUD. Specifically, patients with diabetes who are treated with GLP-1RAs experience better SUD-related outcomes compared to those treated with other antihyperglycemic drugs. A nationwide US Department of Veterans Affairs cohort study found reduced risk of substance use and psychotic disorders with GLP-1RA initiation compared to non-GLP-1RA antihyperglycemics (Xie et al., 2025). Another study across 136 US healthcare systems found patients with OUD or AUD who received GLP-1RAs had significantly lower rates of opioid overdose and alcohol intoxication, and these protective effects were consistent in subgroups with comorbid type 2 diabetes and obesity (Qeadan et al., 2025). Another retrospective cohort study in individuals with obesity found that semaglutide, compared to non-GLP-1RA anti-obesity medications, was associated with lower risk of incident cannabis use disorder in patients with no prior diagnosis, and recurrent diagnosis in patients with history of cannabis use disorder (Wang et al., 2024).
While there have been recent reports reviewing publications based on preclinical studies, clinical trials, and electronic health records data on the effects of GLP-1RAs for SUDs (Bruns Vi et al., 2024, Shen et al., 2024, Sinha and Ghosal, 2025, Yammine et al., 2025), there is still a need to understand the landscape of ongoing clinical trials of GLP-1RAs for SUDs which have been registered but may not be published yet. This is driven in part by the robust pipeline of medications in development for metabolic disorders that target other peptide hormone receptors in addition to GLP-1R (Alfaris et al., 2024, Dos Santos Barbosa et al., 2025), including glucose-dependent insulinotropic peptide receptor (GIPR) agonist such as brenipatide (NCT07223840); glucagon receptor agonist such as pemvidutide (Noureddin et al., 2025) and mazdutide (Ji et al., 2025); amylin receptor agonist such as CagriSema (Davies et al., 2025, Garvey et al., 2025)); glucagon and GIP receptors such as retatrutide, a triple agonist, (Jastreboff et al., 2023); and GIPR antagonist such as maridebart cafraglutide which is administered as monthly injection (Jastreboff et al., 2025). Additionally, orforglipron, a novel small molecule non-peptide GLP-1RA may also be promising (Rosenstock et al., 2025, Wharton et al., 2025, Wharton et al., 2023) given its oral route of administration and similar effects in the brain to the injected peptide GLP-1RAs (Sloop et al., 2024). Therefore, characterizing the ongoing and upcoming clinical trials of GLP-1RAs may inform the therapeutic pipeline of repurposing/developing these medications for SUDs.
The rationale for studying dual/triple agonists (i.e., mediations that target receptors for peptide hormones in addition to GLP-1R) is based in part on the superior metabolic effects of the only FDA approved dual agonist (tirzepatide; dual GLP-1R/GIPR agonist) as compared to GLP-1R-only agonist (Rodriguez et al., 2024). A recent randomized controlled trial (RCT) found greater weight loss and reduction in waist circumference with tirzepatide (10–15 mg/week) versus semaglutide (1.7–2.4 mg/week) (Aronne et al., 2025). Tirzepatide was also more effective than other FDA-approved GLP-1RAs in reducing levels of glycated hemoglobin in RCTs of adults with type 2 diabetes (versus dulaglutide 1.5 mg (Frias et al., 2018) and 0.75 mg/week (Inagaki et al., 2022), and semaglutide 1 mg/week (Frías et al., 2021)). Preclinical models of neurodegeneration suggest that dual GLP-1R/GIPR agonists may be more effective than GLP-1R-only agonists (Maskery et al., 2020, Yuan et al., 2017). However, similar preclinical evidence for SUD is lacking and it remains unclear whether this dual GLP-1R/GIPR agonist property confers greater efficacy (versus GLP-1R-only agonists) for the treatment of SUDs. The greater weight loss-promoting effects of dual/triple agonists (versus GLP-1R-only agonists) may be a potential concern for individuals with SUD using stimulants (such as those with stimulant use disorder) given that use of stimulants can be associated with appetite suppression/weight loss (Jeffers and Benotsch, 2014, Lv et al., 2016).
Therefore, given this active research area of upcoming and planned trials, we undertook a systematic review of clinicaltrials.gov to supplement the knowledge from recently completed systematic review of published studies (Bruns Vi et al., 2024, Shen et al., 2024, Sinha and Ghosal, 2025, Yammine et al., 2025), and focused on key aspects of trials that were registered in clinicaltrials.gov, such as the specific SUDs being studied, specification of eligibility criteria regarding SUD and body mass index, the duration of treatment, the primary and secondary outcome measures, and the sample sizes.
2.Methods
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) standards. A comprehensive search for clinical trials involving glucagon-like peptide-1 receptor agonists (GLP-1RAs) for substance use disorders (SUDs) was conducted on July 3, 2025 using the ClinicalTrials.Gov database. This is registered as open registration on OSF (preregistered at: https://osf.io/x58ne/) as this is an active research area with potential of updating our research results in a future publication.
ClinicalTrials.Gov was searched to identify trials using GLP-1RAs to treat SUDs from inception until July 2, 2025 using root search terms: “GLP-1”, “Semaglutide”, “Exenatide”, “Tirzepatide”, “Liraglutide”, “Dulaglutide”, and “Lisexenatide”. Each root search term was combined with substance search terms including: “nicotine”, “smoking”, “alcohol”, “cannabis”, “marijuana”, “methamphetamines”, “amphetamines”, “cocaine”, “crack”, “stimulant”, “opioid”, “heroin”, and “fentanyl.” Two authors conducted these searches independently and the senior author then reviewed all the search terms.
Trials were first screened by title and study overview, then inclusion criteria. Trials were included if they (a) had endpoints measuring substance use (i.e., proportion of negative UDS, Timeline Followback, self-reported craving), and (b) utilized a GLP-1RA for the treatment of SUDs (opioid use disorder, alcohol use disorder, methamphetamine use disorder, cocaine use disorder, nicotine/tobacco use disorder, and cannabis use disorder) with or without comorbid conditions (i.e., obesity, type 2 diabetes). Trials were excluded if they excluded individuals with SUDs.
3.Results
This systematic review of ClinicalTrials.Gov identified 192 trials via search term and title criteria, with 33 trials satisfying inclusion criteria. The most common reasons for exclusion from this review included the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for a medical condition other than substance use disorder (SUD) (e.g., osteoarthritis, diabetes, obesity, cardiovascular disease) and absence of a SUD and/or GLP-1RA treatment group. Included studies were most numerous for alcohol use disorder (N = 15) followed by tobacco/nicotine use disorder (N = 9), cocaine use disorder (N = 4), opioid use disorder (N = 4), and methamphetamine use disorder (N = 1). There were no clinical trials of GLP-1RAs for cannabis use disorder. Semaglutide was the most studied GLP-1RA (including one study in combination with cagrilintide) (N = 15), followed by exenatide (N = 8), tirzepatide (N = 6), liraglutide (N = 2), dulaglutide (N = 1), and pemvidutide (N = 1).
Of the included studies, nine studies are located outside of the United States, see Table 1, Table 2. Thresholds of body mass index (BMI) for study inclusion were highly variable, with some studies excluding underweight or normal weight individuals. Duration of study was also highly variable with durations ranging from 5 days to 32 weeks. Diagnosis of SUD were typically based on structured diagnostic measures and Diagnostic and Statistical Manual Fifth Edition (DSM-5) criteria (American Psychiatric Association (APA), 2013). Primary outcomes focused on reduction of substance use, however, studies varied in how they measured this reduction with some studies focusing on clinical measures (such as the Fagerstrom test for nicotine dependence, cue craving visual analog score, Timeline Followback) and others including biologic data (i.e., Phosphatidylethanol values, urine drug screen).
| Trial ID | Substance use related eligibility criteria | BMI Cutoff | Study Status | Estimated start and end dates | Target enrollment number | Interventions | Comparator | Primary outcome | Study Duration | Key secondary outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT05895643 | Alcohol dependence per ICD-10, AUD per DSM-5. AUDIT > 15. Heavy alcohol drinking defined as more than 6 days with alcohol consumption over 4 units (48 g alcohol) for women and 5 units (60 g alcohol) for men during a consecutive 30-day period, within 40 days prior to baseline evaluation. | Inclusion: ≥30 kg/m2 | Active, not recruiting | 6/13/2023–9/2025 | 108 | Semaglutide | Placebo injection | Change in heavy drinking days | 26 weeks | Change in heavy drinking days adjusted for semaglutide dose and weight loss. Total alcohol consumption. Drinks per day. Days without alcohol consumption. Time to relapse. Time to relapse (heavy drinking day). WHO risk levels of alcohol consumption. PACS score. AUDIT score. |
| NCT05520775 | AUD per DSM-5 and NIAAA criteria for current at-risk drinking (i.e., >7/14 drinks in one week for women/men, with at least two episodes of 4+/5 + drinks in the past 30 days) | None | Completed | 9/2/2022–4/19/2024 | 48 | Semaglutide | Placebo injection | Change in alcohol consumed and in BAC. | 10 weeks | Change in subjective stimulation and sedation on Biphasic Alcohol Effects Scale. Change in Alcohol Demand on Alcohol Purchase Task. Change in Cigarette Demand on Cigarette Purchase Task). Change in daily alcohol and daily cigarette use. |
| NCT03645408 | Exceeds safe weekly drinking limits (4 SDUs for women or 21 SDUs for men per week). At least one episode of binge drinking (>3 SDUs for women, >4 SDUs for men) per week in the four weeks prior to baseline screening. AUD per DSM-5. | Exclusion: <18 or ≥ 30 kg/m2. | Terminated | 5/2/2019–7/1/2021 | 8 | Exenatide then placebo | Placebo then exenatide | Alcohol consumption | N/A | N/A |
| NCT06546384 | AUDIT-C ≥ 4 for women and ≥ 5 for men. | Inclusion: ≥35 or ≥ 28 kg/m2 with weight-related co-morbidities. | Not yet recruiting | 6/1/2025–4/30/2027 | 64 | Semaglutide | Behavioral: Weight reduction recommendations | Proportion achieving negative PEth test | 16 weeks | Proportion achieving total alcohol abstinence (per TLFB), maintaining total alcohol abstinence (per negative ethylglucoronide test). Change in alcohol abstinent days (per TLFB), heavy drinking days (per TLFB), total number of drinks per week (per TLFB). Effects on reward and relief drinking behavior. |
| NCT06015893 | AUD per DSM-5, >7 drinks/week for females or > 14 drinks/week for males during the 28-day period prior to screening plus at least four days with > 3 drinks for females or > 4 drinks for males during the 28-day period prior to screening, Most recent CIWA-Ar score < 10 | Exclusion: <25 or ≥ 50 kg/m2 | Recruiting | 10/17/2023 | 52 | Semaglutide | Behavioral: Take Control + Placebo | Reduction in alcohol drinking. Safety and tolerability of semaglutide. | 20 weeks | Reduction in other self-reported alcohol-related outcomes, and blood PEth levels. Reduction in alcohol/food cue-elicited craving assessed in a bar-like laboratory. |
| NCT05891587 | AUD per DSM-5, >7 drinks/week for females or > 14 drinks/week for males during the 28-day period prior to screening plus at least four days with > 3 drinks for females or > 4 drinks for males during the 28-day period prior to screening, Most recent CIWA-Ar score ≤ 10. | Exclusion: <25 or ≥ 50 kg/m2 | Recruiting | 07/07/2023 | 80 | Semaglutide | Placebo injections | Change in alcohol drinking | 12 weeks | Change in heavy drinking days, drinks per drinking days, PEth levels, and brain activity in response to alcohol cues during fMRI cue reactivity task. Safety and tolerability of semaglutide. |
| NCT06994338 | Moderate-to-severe AUD, average daily consumption of ≥ 40 g (women) / ≥60 g (men) per day in the 28 days prior to baseline | Inclusion: ≥27 kg/m2 | Not yet recruiting | 06/2025–0/2026 | 42 | Tirzepatide | Placebo | Number of heavy drinking days | 8 weeks | N/A |
| NCT06987513 | Moderate-to-severe AUD. Reported ≥ 28 drinks/week if male or ≥ 21 drinks/week if female in the 28 days prior to informed consent; including at least 3 heavy drinking days/week (defined as ≥ 5 drinks/day for male and ≥ 4 drinks/day for female) | Inclusion: ≥25 kg/m2 | Recruiting | 5/15/2025–9/30/2026 | 100 | Pemvidutide 2.4 mg | Placebo | Change in the average number of heavy drinking days/week | 24 weeks | Proportion of subjects achieving a 2-level reduction in WHO risk drinking level (per TLFB) during Weeks 21–24. Change in PEth levels at Week 24 |
| NCT03232112 | Alcohol dependence per ICD-10. AUDIT score > 15. Heavy alcohol drinking defined as having alcohol consumption over 60 g of alcohol/day (men) or 48 g of alcohol/day (women) for at least 5 days in the past 30 days. | Inclusion: >18.5 kg/m2 | Completed | 8/7/2017–10/05/2020 | 152 | Exenatide 2 mg | Placebo | Heavy drinking days | 26 weeks | Total alcohol consumption, PACS, AUDIT and DUDIT score. |
| NCT06727331 | Admitted for the treatment of alcohol withdrawal. AUD per DSM-5. | Inclusion: >25 kg/m2 | Not yet recruiting | 05/2025–07/2026 | 20 | Tirzepatide | Saline Placebo | Cue-induced cravings for Alcohol. | 6 weeks | PAC). Percent days abstinent and heavy drinking days. Drinks per drinking day. |
| NCT06409130 | Patient-reported history of alcohol overuse for ≥ 5 years with an alcohol history of a mean of ≥ 50 g (male) or ≥ 40 g (female) per day for the last year leading up to the time of signing informed consent. | Exclusion: ≤25 kg/m2. | Active, not recruiting | 5/20/24–1/1/2026 | 270 | NNC0194-0499 + semaglutide + cagrilintide | Cagrilintide placebo + semaglutide placebo, NNC0194-0499 placebo + semaglutide placebo | Change in enhanced liver fibrosis | 28 weeks | Change in PEth and change in alcohol amount measured by TLFB. |
| NCT06939088 | Alcohol dependence per ICD-10, and AUD per DSM-5. Heavy Alcohol Consumption: ≥4 heavy drinking days (≥48 g for women and ≥ 60 g for men) within a consecutive 21-day period during the 28 days preceding the baseline evaluation. | Inclusion: ≥23 kg/m2 | Recruiting | 5/5/25–12/31/2028 | 108 | Tirzepatide | Placebo | Change in heavy drinking days | 26 weeks | Total alcohol consumption. Days without alcohol consumption. WHO risk levels of alcohol consumption. PACS, AUDIT, FTND and DUDIT score. Drug use frequency. Number of cigarettes smoked/day. Blood PEth levels. fMRI alcohol cue-reactivity. |
| NCT05892432 | Moderate-to-severe AUD per DSM-5 using MINI. | Inclusion: >25 kg/m2 | Recruiting | 1/11/24–6/30/2025 | 135 | Semaglutide 3 mg/day for four weeks and 7 mg/day oral for four weeks, oral | Placebo | Change in cue craving VAS | 8 weeks | Number of drinks per day. Percentage of heavy drinking days. Change in alcohol cue-elicited brain activation. |
| NCT07046819 | AUD per MINI; current alcohol per TLFB (>14 standard drinks/week for males and > 7 standard drinks/week for females for the last 8 weeks). Liver steatosis (CAP score > 240) | Inclusion: ≥25 and < 40 kg/m2 | Not yet recruiting | 09/10/2025 | 120 | Tirzepatide | Placebo | Percentage reduction of body weight and CAP score. | 12 weeks | Reduction in 1) liver steatosis as measured by MRI spectroscopy, 2) MRI visceral fat, 3) liver enzymes, 4) drinking behaviors/cravings, and 5) WHO risk drinking level |
| NCT07040592 | AUD per DSM-5 and AUDIT-C screen. PEth > 20 ng/ml | Exclusion: <23 kg/m2 | Not yet recruiting | 7/1/25 | 30 | Semaglutide | None | Completion of enrollment and duration of sessions | 12 weeks | Change in self-reported alcohol use (number of days of alcohol use and number of drinks per day) and PEth. |
| Trial ID | Substance use related eligibility criteria | BMI Cutoff | Study Status | Estimated start and end date | Target enrollment number | Interventions | Comparator | Primary outcome | Study Duration | Key secondary outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT06548490 | Moderate-to-severe OUD per DSM-5. Receiving outpatient treatment and at least 2 weeks on BUP or 4 weeks on methadone at the time of enrollment. Have at least 1 urine test positive for opioids, and positive self-reporting of opioid use. | Inclusion: >18 kg/m2 | Recruiting | 1/13/25–11/2026 | 200 | Semaglutide | Placebo | Abstinent from illicit and nonprescribed opioids. | 13 weeks | Self-reported opioid craving scores. Sustained abstinence from opioid use. Abstinence from stimulants use. Days of stimulant use and opioid use (per TLFB). |
| NCT06651177 | Moderate-to-severe OUD | Inclusion: ≥25 kg/m2 | Not yet recruiting | 9/16/25–2/10/2027 | 310 | Tirzepatide | Placebo | 6-month MOUD retention rate, UDS. | 6 months | Proportion of illicit opioid-negative UDS and negative UDS for other substances. Substance use days. Opioid craving and withdrawal symptoms. Non-Opioid Drug and Alcohol Craving. |
| NCT06639464 | Severe OUD per DSM-5 | Exclusion: <25 mg/kg2 | Recruiting | 06/2025–03/2027 | 46 | Semaglutide | Placebo | Cue-induced cravings. Relapse. | 14 weeks | Visual probe task |
| NCT04199728 | OUD and planning on being enrolled in a residential treatment center for a minimum of 4 weeks | None | Completed | 10/18/21–9/13/2023 | 27 | Liraglutide | Placebo | Cue-elicited and ambient craving on VAS. | 4 weeks | Change in blood oxygenation level response to visual opioid drug cues in prefrontal cortex using functional near infrared spectroscopy. |
| NCT06924697 | A history of smoking for at least one year. FTND score ≥ 4. | None | Enrolling by Invitation | 6/21/25–7/1/2026 | Semaglutide | DPP-4i | FTND score | Baseline to 24 weeks | fMRI changes (weeks 0 and 24), clinical laboratory tests (weeks 0, 12, and 24), exhaled carbon monoxide test (weeks 0, 12, and 24), | |
| NCT03712098 | Self-report smoking cigarettes (menthol and non-menthol) at least 10 times/day, on average, for the past 6 months. | Inclusion: ≥27 kg/m2 with one weight-related comorbidity or ≥ 30 kg/m2 | Completed | 11/29/2018–5/25/2022 | 40 | Smoking cessation counseling and liraglutide | Smoking cessation counseling and placebo | 7-day point prevalence smoking abstinence at 12 and 26 weeks post-target quit date. | 32 weeks | Body weight at 12 and 26 weeks post-target quit date. |
| NCT05530577 | Smoking 5 + cigarettes/day (on average) over the past year, with no period of abstinence > 90 days. Biochemical verification of smoking status, based on expired CO > 8 ppm at baseline | None | Completed | 10/7/2022–5/13/2024 | 24 | Semaglutide | Placebo | Change in nicotine self-administration and reinstatement duration. | 10 weeks | Change in daily cigarette smoking |
| NCT02975297 | Have smoked ≥ 10 cigarettes a day for at least one year and provide a breath carbon monoxide (CO) ≥ 10 ppm; | Inclusion: ≥25 kg/m2 | Completed | 07/2016–1/3/2020 | 84 | Exenatide | Placebo + NRT plus counseling | Post-quit craving, withdrawal symptoms, and cue-induced craving. | 10 weeks | Number of participants who self-reported abstinence and were biochemically verified as abstinent via expired CO Level of ≤ 5 ppm |
| NCT06173778 | Have been smoking ≥ 5 cigarettes per day for at least 1 year (prior to screening) and provide positive cotinine test. | Inclusion: ≥30 kg/m2 or ≥ 27 kg/m2 with at least one weight-related comorbidity | Recruiting | 4/23/2024–8/1/2024 | 197 | Semaglutide | placebo | Change in percent body weight | 28 weeks | No smoking related outcomes |
| NCT05610800 | Have been smoking ≥ 5 cigarettes per day for at least 1 year and provide positive cotinine test | Inclusion: ≥25 kg/m2 | Recruiting | 7/12/2022–1/30/2026 | 140 | Exenatide | Placebo | Abstinence between weeks 11 through 14 and biochemically verified | 15 weeks | Weight |
| NCT06986993 | Report daily use of > 2 cigarettes per day (CPD), as this is a sufficient threshold for detecting tobacco use disorder | Inclusion: ≥30 kg/m2 | Recruiting | 7/1/2024–6/30/2028 | 40 | Semaglutide | Placebo | Cigarette smoking | 12 weeks | Weight |
| NCT03204396 | Daily smokers who are willing to quit and either ≥ 10 cigarettes/day, FTND score ≥ 5, tobacco-associated disease, or treatment with varenicline. | Inclusion: 18–30 kg/m2 | Completed | 6/26/2017–8/30/2022 | 256 | Dulaglutide | 0.5 ml normal saline | Abstinence at week 12 | 52 weeks | Change in body weight |
| NCT02690987 | Nicotine use disorder or AUD per DSM-5 but who are in early stable abstinence (>6 weeks). | Inclusion: 28.0–50.0 kg/m2. | Unknown | 08/2015–08/2020 | 95 | Exenatide, desacyl ghrelin | Placebo | fMRI activation during cigarette, alcohol and food picture evaluation task | 4 years | Resting-state fMRI measure of limbic network |
| NCT06252623 | Self-reported recent use of smoked or intravenous cocaine verified by a positive urine (≥ 150 ng/mL). Report using cocaine for ≥ 10 years and using ≥ 2 g of cocaine/week | None | Withdrawn | 08/01/2024–12/31/2026 | 0 | Exenatide | Placebo | Proportion of up to 10 active cocaine doses. Subjective effects of cocaine or placebo. | 6 weeks | Incidence of treatment-emergent adverse events |
| NCT02302976 | DSM-IV criteria for cocaine abuse or dependence. Recent street cocaine use in excess of amounts to be administered in the study,positive UDS for cocaine. | None | Completed | 11/2014–08/01/2018 | 13 | Cocaine + Exenatide | Placebo + Exenatide, Placebo + Placebo, Cocaine + Placebo | Mean cocaine inter-infusion interval | 5 days | N/A |
| NCT04941521 | CUD per DSM-5, have at least 1 cocaine-positive urine specimen (≥ 150 ng/mL) during intake. | None | Completed | 06/24/2021–11/17/2021 | 3 | Exenatide and counseling | N/A | Feasibility, safety, cocaine-positive UDS | 6 weeks | Cocaine use on ≥ 50% days of the week. Reduction in craving by Week 6 and proportion of participants who had a decrease in drug demand by week 6. |
| NCT06691243 | Meet criteria for CUD per DSM-5. Used cocaine at least 7 out of the past 14 days. | Inclusion: 20–50 kg/m2 | Not yet recruiting | 07/2025–03/2027 | 40 | Semaglutide | Placebo | Meeting criteria for CUD. Cocaine use ≥ 7 out of 14 days | 16 weeks | Reduction in cocaine use frequency, craving, risk taking behavior, and impulsivity. |
| NCT06745128 | Moderate-to-severe MtUD. Self-report methamphetamine use on ≥ 18 days in the 30-day period prior to written informed consent using TLFB. | Inclusion: ≥30 kg/m2 or ≥ 27 kg/m2 and at least one weight-related comorbidity | Active, not recruiting | 2/3/2025–3/31/2026 | 45 | Tirzepatide | N/A | Self-reported use of methamphetamine (TLFB) | 32 weeks | Feasibility of using tirzepatide in individuals with MtUD |
As shown in Table 1, a majority (N = 7) of trials for alcohol use disorder are studying semaglutide, followed by tirzepatide (N = 4), and exenatide (N = 2). One study (NCT05520775) did not have a BMI criterion, while the remaining 14 excluded underweight individuals with variable BMI cutoffs. Five studies also had variable upper limit for BMI criterion. Of the included studies, two (NCT05520775 and NCT03232112) have been completed and one (NCT03645408) was terminated due to hospital-wide policies that halted recruitment due to novel coronavirus 19 (COVID-19). The EXALT trial (NCT03232112) found that although exenatide did not significantly reduce the number of heavy drinking days compared with placebo, it significantly attenuated functional magnetic resonance imaging alcohol cue reactivity in the ventral striatum and septal areas, regions crucial for drug reward and addiction. Furthermore, this study found lower dopamine transporter availability in the exenatide group compared with placebo. In the obese subgroup, exploratory analysis revealed significantly reduced heavy drinking and alcohol intake in the exenatide group compared with placebo (Klausen et al., 2022). The Semaglutide for Alcohol Use Disorder study (NCT05520775) found that low-dose semaglutide had a medium to large effect size for grams of alcohol consumed and peak breath alcohol concentration. This study also found that semaglutide did not affect average drinks per calendar day or number of drinking days, but significantly reduced drinks per drinking day and weekly alcohol craving (Hendershot et al., 2025).
As shown in Table 2, a majority of trials (N = 4) for nicotine/tobacco use disorder utilized semaglutide, followed by exenatide (N = 3). Two studies did not have a BMI criterion (NCT06924697 and NCT05530577), while six trials excluded participants not overweight/obese. The remaining trial excluded obese participants (NCT03204396). Two of four completed studies have published results. The Exenatide Once Weekly for Smoking Cessation study (NCT02975297) found that exenatide was associated with higher likelihood of smoking abstinence compared to placebo, and that exenatide reduced end-of-treatment craving and withdrawal among abstainers (Yammine et al., 2021). The Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues study (NCT03204396) found no significant difference in abstinence rates between the dulaglutide and placebo groups, and that craving for smoking declined during treatment with no difference between dulaglutide and placebo groups (Lengsfeld et al., 2023). For opioid use disorder, semaglutide was the most frequently studied GLP-1RA, see Table 2. There is one completed study for opioid use disorder without published results. For cocaine use disorder, exenatide (N = 3) was the most frequently studied GLP-1RA; however, one study of exenatide for cocaine use disorder was withdrawn due to the inability to acquire the study drug (NCT06252623). One completed study (NCT02302976) for cocaine use disorder did not have published results whereas another was published as a case series to support feasibility of using exenatide 2 mg subcutaneously once-weekly in an open-label fashion for 6 weeks (Yammine et al., 2023). There is one reported study of tirzepatide for methamphetamine use disorder. There are no studies of GLP-1RAs for cannabis use disorder (Table 2).
After the completion of the review for this report, a Phase 3 program was registered in November 2025 for a novel dual GLP-1R/GIPR agonist (brenipatide) which is seeking to enroll individuals with moderate-to-severe alcohol use disorder in two large (n = 1100 each) RCTs (NCT07219966 and NCT07219953). Additionally, a smaller trial (n = 222) is also evaluating the effect of this medication in individuals who recently quit smoking and are motivated to stay quit (NCT07223840).
4.Discussion
This systematic review of clinical trials focusing on glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of substance use disorders (SUDs) has several important findings. Firstly, alcohol use disorder (AUD) was the most extensively studied SUD, followed by nicotine/tobacco use disorder, and cocaine use disorder. There was only one trial for methamphetamine use disorder, and no clinical trials for cannabis use disorder. Semaglutide was the most studied GLP-1RA for AUD and nicotine use disorder, while exenatide was the most studied GLP-1RA for cocaine use disorder. Included studies had a wide range of body mass index (BMI) cutoffs, length of study, methods of measurement of SUD-related outcomes, and primary outcome measures.
Although there are several medication options for both AUD and nicotine/tobacco use disorder, patients with co-morbid obesity or with contraindications to current modalities would likely benefit from the use of GLP-1RA as part of their treatment approach. However, the variability in eligibility criteria based on BMI as a measure of obesity may raise concerns for the therapeutic potential of GLP-1RAs in normal/underweight individuals. Greater access to potential therapeutic options for SUDs (such as GLP-1RAs in primary care settings if shown to be effective in ongoing/future trials) may enable higher treatment initiation and maintenance. Furthermore, with disorders such as cocaine use disorder, methamphetamine use disorder, and cannabis use disorder, there are no Food and Drug Administration (FDA) approved therapies, leaving a gap in care that GLP-1RAs may be able to fill. However, there is a paucity of ongoing/upcoming clinical trials of GLP-1RAs for these disorders despite studies based on electronic health records suggesting their therapeutic potential (Wang et al., 2024, Xie et al., 2025).
The included studies in this review suggest that the overall number of trials are low and there are a wide variety of approaches being used in measuring the utility of GLP-1RAs for the treatment of SUD. The variability in approaches likely reflects the differences in guidance for different SUDs from regulatory agencies like the FDA. However, greater effort is needed for harmonization of endpoints that are consistent with FDA’s guidance within SUD category (FDA, 2020, FDA, 2023, Witkiewitz et al., 2025) and the need to characterize the changes in use of other substances in individuals with polysubstance use.
Existing studies support the link between SUDs and obesity (Bliss and Whiteside, 2018, Brutman et al., 2019), arguing that the similar biological pathways responsible for pathologic consumption of highly palatable food may also responsible for pathologic consumption of other substances (Leggio et al., 2025, Volkow et al., 2013). Therefore, it is encouraging that several ongoing studies are assessing changes in brain activity in response to drug cues as well as food cues after treatment with GLP-1RAs. However, studies are needed to further elucidate the mechanisms by which these relatively large molecules (peptides) affect the function of GLP-1Rs in brain. Further research with GLP-1RAs would also allow for determination of therapeutic dosage and duration, long term efficacy, and safety profile and tolerability within the SUD population. Systematic efforts to identify patient characteristics that are associated with higher likelihood of therapeutic benefits for SUDs are also needed. All of the ongoing studies in SUD have used GLP-1RAs that are injected subcutaneously (except one of oral semaglutide), and future studies are needed with orally available compounds (potentially increase acceptability and access) (Rosenstock et al., 2025, Wharton et al., 2025, Wharton et al., 2023) and with longer duration of action (such as monthly injections which may improve compliance) (Jastreboff et al., 2025).
5.Conclusion
Substance use disorders remain prevalent, with high rates of morbidity and mortality, and few therapeutic options. There is a large unmet need especially for substance use disorders like cocaine use disorder, methamphetamine use disorder, and cannabis use disorder with no current Food and Drug Administration (FDA) approved medications. This review of completed and ongoing clinical trials revealed that glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being mostly commonly studied in individuals with alcohol use disorder. While GLP-1RAs may represent a paradigm shift for treating substance use disorders, randomized controlled trials for methamphetamine and cannabis use disorders are lacking. Future trials should utilize harmonized endpoints based on FDA guidance to define efficacy and safety and test next-generation GLP-1RAs, including those available orally and with longer duration of action.
Funding
This work was supported by the O’Donnell Brain Institute Clinical Neuroscience Endowed Scholar Award to Manish Jha.
Declaration of competing interest
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: In the past 36 months, Dr. Jha has received contract research grants from Neurocrine Bioscience, Navitor/Supernus and Janssen Research & Development; honorarium to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network and as Guest Editor for Psychiatric Clinics of North America from Elsevier; consultant fees from Janssen Scientific Affairs, Sanofi, Neurocrine, AbbVie, MindMed and Boehringer Ingelheim; fees to serve on Data Safety and Monitoring Board for Worldwide Clinical Trials (Eliem, Skye and Inversargo), Vicore Pharma and IQVIA (Click); and honoraria for educational presentations from North American Center for Continuing Medical Education, Medscape/WebMD, Clinical Care Options, Physicians’ Education Resource, Efficient CME, Soterix, and H.C. Wainwright & Co. Others authors have no conflicts of interest to disclose.
Data availability
No data was used for the research described in the article.
References
Untitled section
References
- Alfaris N., Waldrop S., Johnson V., Boaventura B., Kendrick K., Stanford F.C. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: A narrative review. EClinicalMedicine. 2024;75 doi: 10.1016/j.eclinm.2024.102782.
- American Psychiatric Association (APA) (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596.
- Aronne L.J., Horn D.B., le Roux C.W., Ho W., Falcon B.L., Gomez Valderas E., Das S., Lee C.J., Glass L.C., Senyucel C., Dunn J.P. Tirzepatide as compared with semaglutide for the treatment of obesity. The New England Journal of Medicine. 2025;393(1):26–36. doi: 10.1056/NEJMoa2416394.
- Bell J., Strang J. Medication treatment of opioid use disorder. Biological Psychiatry. 2020;87(1):82–88. doi: 10.1016/j.biopsych.2019.06.020.
- Bliss E.S., Whiteside E. The gut-brain axis, the human gut microbiota and their integration in the development of obesity. Frontiers in Physiology. 2018;9:900. doi: 10.3389/fphys.2018.00900.
- Bruns Vi N., Tressler E.H., Vendruscolo L.F., Leggio L., Farokhnia M. IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacological Research. 2024;207 doi: 10.1016/j.phrs.2024.107312.
- Brutman J.N., Sirohi S., Davis J.F. Recent advances in the neurobiology of altered motivation following bariatric surgery. Current Psychiatry Reports. 2019;21(11):117. doi: 10.1007/s11920-019-1084-2.
- Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team, & IRETA Team (2024). The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Journal of addiction medicine, 18 (1S Suppl 1), 1–56. https://doi.org/10.1097/ADM.0000000000001299.
- Collins L., Costello R.A. StatPearls: StatPearls Publishing. Copyright © 2025. StatPearls Publishing LLC; 2025. Glucagon-like peptide-1 receptor agonists.
- Davies M.J., Bajaj H.S., Broholm C., Eliasen A., Garvey W.T., le Roux C.W., Lingvay I., Lyndgaard C.B., Rosenstock J., Pedersen S.D. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 Diabetes. The New England Journal of Medicine. 2025;393(7):648–659. doi: 10.1056/NEJMoa2502082.
- Dos Santos Barbosa L.A., Almarie B., Moreira E.L.G. Incretin dominance and emerging mechanisms in obesity pharmacotherapy: Insights from 275 registered clinical trials (2019-2024) Therapeutic Innovation & Regulatory Science. 2025 doi: 10.1007/s43441-025-00875-y.
- Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., & Benrick, A. (2025). Tirzepatide attenuates dopamine reward signaling and suppresses alcohol drinking and relapse-like behaviors in rodents. bioRxiv, 2025.2008. 2026.672374.
- Fda . Silver Spring; MD: 2020. Opioid use disorder: Endpoints for demonstrating effectiveness of drugs for treatment guidance for industry.
- Fda . Center for Drug Evaluation and Research (CDER); 2023. Stimulant use disorders: Developing drugs for treatment. US Department of Health and Human Services Food and Drug Administration.
- Frias J.P., Nauck M.A., Van J., Kutner M.E., Cui X., Benson C., Urva S., Gimeno R.E., Milicevic Z., Robins D., Haupt A. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–2193. doi: 10.1016/s0140-6736(18)32260-8.
- Frías J.P., Davies M.J., Rosenstock J., Pérez Manghi F.C., Fernández Landó L., Bergman B.K., Liu B., Cui X., Brown K. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine. 2021;385(6):503–515. doi: 10.1056/NEJMoa2107519.
- Garvey W.T., Blüher M., Osorto Contreras C.K., Davies M.J., Winning Lehmann E., Pietiläinen K.H., Rubino D., Sbraccia P., Wadden T., Zeuthen N., Wilding J.P.H. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. The New England Journal of Medicine. 2025;393(7):635–647. doi: 10.1056/NEJMoa2502081.
- Han B., Compton W.M., Jones C.M., Einstein E.B., Volkow N.D. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. JAMA Psychiatry. 2021;78(12):1329–1342. doi: 10.1001/jamapsychiatry.2021.2588.
- Hendershot C.S., Bremmer M.P., Paladino M.B., Kostantinis G., Gilmore T.A., Sullivan N.R., Tow A.C., Dermody S.S., Prince M.A., Jordan R., McKee S.A., Fletcher P.J., Claus E.D., Klein K.R. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405. doi: 10.1001/jamapsychiatry.2024.4789.
- Inagaki N., Takeuchi M., Oura T., Imaoka T., Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): A double-blind, multicentre, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology. 2022;10(9):623–633. doi: 10.1016/s2213-8587(22)00188-7.
- Jastreboff A.M., Kaplan L.M., Frías J.P., Wu Q., Du Y., Gurbuz S., Coskun T., Haupt A., Milicevic Z., Hartman M.L. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 Trial. The New England Journal of Medicine. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972.
- Jastreboff A.M., Ryan D.H., Bays H.E., Ebeling P.R., Mackowski M.G., Philipose N., Ross L., Liu Y., Burns C.E., Abbasi S.A., Pannacciulli N. Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial. The New England Journal of Medicine. 2025;393(9):843–857. doi: 10.1056/NEJMoa2504214.
- Jeffers A.J., Benotsch E.G. Non-medical use of prescription stimulants for weight loss, disordered eating, and body image. Eating Behaviors. 2014;15(3):414–418. doi: 10.1016/j.eatbeh.2014.04.019.
- Ji L., Jiang H., Bi Y., Li H., Tian J., Liu D., Zhao Y., Qiu W., Huang C., Chen L., Zhong S., Han J., Zhang Y., Lian Q., Yang P., Lv L., Gu J., Liu Z. Once-weekly mazdutide in chinese adults with obesity or overweight. The New England Journal of Medicine. 2025;392(22):2215–2225. doi: 10.1056/NEJMoa2411528.
- Klausen M.K., Jensen M.E., Møller M., Le Dous N., Jensen A., Zeeman V.A., Johannsen C.F., Lee A., Thomsen G.K., Macoveanu J., Fisher P.M., Gillum M.P., Jørgensen N.R., Bergmann M.L., Enghusen Poulsen H., Becker U., Holst J.J., Benveniste H., Volkow N. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19) doi: 10.1172/jci.insight.159863.
- Leggio L., Farokhnia M., Kenny P.J., Pepino M.Y., Simmons W.K. Crosstalk between alcohol use disorder and obesity: Two sides of the same coin? Molecular Psychiatry. 2025;30(12):5938–5952. doi: 10.1038/s41380-025-03259-8.
- Lengsfeld S., Burkard T., Meienberg A., Jeanloz N., Vukajlovic T., Bologna K., Steinmetz M., Bathelt C., Sailer C.O., Vogt; D.R., Hemkens L.G., Speich B., Urwyler S.A., Kühne J., Baur F., Lutz L.N., Erlanger T.E., Christ-Crain M., Winzeler B. Effect of dulaglutide in promoting abstinence during smoking cessation: A single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 2023;57 doi: 10.1016/j.eclinm.2023.101865.
- Lv D., Zhang M., Jin X., Zhao J., Han B., Su H., Zhang J., Zhang X., Ren W., He J. The body mass index, blood pressure, and fasting blood glucose in patients with methamphetamine dependence. Medicine (Baltimore) 2016;95(12):e3152. doi: 10.1097/MD.0000000000003152.
- Marquez-Meneses J.D., Olaya-Bonilla S.A., Barrera-Carreño S., Tibaduiza-Arévalo L.C., Forero-Cárdenas S., Carrillo-Vaca L., Rojas-Rodríguez L.C., Calderon-Ospina C.A., Rodríguez-Quintana J. GLP-1 Analogues in the neurobiology of addiction: translational insights and therapeutic perspectives. International Journal of Molecular Sciences. 2025;26(11) doi: 10.3390/ijms26115338.
- Martin C.K., Carmichael O.T., Carnell S., Considine R.V., Kareken D.A., Dydak U., Mattes R.D., Scott D., Shcherbinin S., Nishiyama H., Knights A., Urva S., Biernat L., Pratt E., Haupt A., Mintun M., Otero Svaldi D., Milicevic Z., Coskun T. Tirzepatide on ingestive behavior in adults with overweight or obesity: A randomized 6-week phase 1 trial. Nature Medicine. 2025;31(9):3141–3150. doi: 10.1038/s41591-025-03774-9.
- Maskery M., Goulding E.M., Gengler S., Melchiorsen J.U., Rosenkilde M.M., Hölscher C. The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 2020;35 doi: 10.1177/1533317520953041.
- McPheeters M., O'Connor E.A., Riley S., Kennedy S.M., Voisin C., Kuznacic K., Coffey C.P., Edlund M.D., Bobashev G., Jonas D.E. Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis. Journal of the American Medical Association. 2023;330(17):1653–1665. doi: 10.1001/jama.2023.19761.
- Nielsen S., Gowing L., Sabioni P., Le Foll B. Pharmacotherapies for Cannabis Dependence. The Cochrane Database of Systematic Reviews. 2019;1 doi: 10.1002/14651858.CD008940.pub3.
- Noureddin M., Harrison S.A., Loomba R., Alkhouri N., Chalasani N., Sheikh M.Y., Tomah S., Gutierrez J.A., Urbina S., Suschak J.J., Brown R., Odili O., Yang J., Keeton S., Neff G., Mena E., Roberts M.S., Browne S.K., Harris M.S. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025;406(10520):2644–2655. doi: 10.1016/s0140-6736(25)02114-2.
- Perry C., Liberto J., Milliken C., Burden J., Hagedorn H., Atkinson T., McKay J.R., Mooney L., Sall J., Sasson C., Saxon A., Spevak C., Gordon A.J. The management of substance use disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals of Internal Medicine. 2022;175(5):720–731. doi: 10.7326/m21-4011.
- Qeadan F., McCunn A., Tingey B. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. 2025;120(2):236–250. doi: 10.1111/add.16679.
- Rodriguez P.J., Goodwin Cartwright B.M., Gratzl S., Brar R., Baker C., Gluckman T.J., Stucky N.L. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Internal Medicine. 2024;184(9):1056–1064. doi: 10.1001/jamainternmed.2024.2525.
- Rosenstock J., Hsia S., Nevarez Ruiz L., Eyde S., Cox D., Wu W.S., Liu R., Li J., Fernández Landó L., Denning M., Ludwig L., Chen Y. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. The New England Journal of Medicine. 2025;393(11):1065–1076. doi: 10.1056/NEJMoa2505669.
- Selby P., Zawertailo L. Tobacco Addiction. The New England Journal of Medicine. 2022;387(4):345–354. doi: 10.1056/NEJMcp2032393.
- Shen M.R., Owusu-Boaitey K., Holsen L.M., Suzuki J. The efficacy of GLP-1 agonists in treating substance use disorder in patients: A scoping review. Journal of Addiction Medicine. 2024;18(5):488–498. doi: 10.1097/adm.0000000000001347.
- Sinha B., Ghosal S. The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: A systematic review and meta-analysis. Addiction Science & Clinical Practice. 2025 doi: 10.1186/s13722-025-00637-z.
- Sloop K.W., Cox A.L., Wainscott D.B., White A., Droz B.A., Stutsman C., Showalter A.D., Suter T.M., Dunbar J.D., Snider B.M., O'Farrell L.S., Hewitt N., Ruble J.C., Padgett L.R., Woerly E.M., Peterson J.A., Coskun T., Liu Z., Coutant D., Willard F.S. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Science Translational Medicine. 2024;16(778) doi: 10.1126/scitranslmed.adp5765.
- Volkow N.D., Xu R. GLP-1R agonist medications for addiction treatment. Addiction. 2025;120(2):198–200. doi: 10.1111/add.16626.
- Volkow N.D., Wang G.J., Tomasi D., Baler R.D. Obesity and addiction: Neurobiological overlaps. Obesity Reviews : An Official Journal of the International Association for the Study of Obesit. 2013;14(1):2–18. doi: 10.1111/j.1467-789X.2012.01031.x.
- Wang W., Volkow N.D., Berger N.A., Davis P.B., Kaelber D.C., Xu R. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: A retrospective cohort study. Molecular Psychiatry. 2024;29(8):2587–2598. doi: 10.1038/s41380-024-02498-5.
- Wharton S., Blevins T., Connery L., Rosenstock J., Raha S., Liu R., Ma X., Mather K.J., Haupt A., Robins D., Pratt E., Kazda C., Konig M. Daily Oral GLP-1 Receptor agonist orforglipron for adults with obesity. The New England Journal of Medicine. 2023;389(10):877–888. doi: 10.1056/NEJMoa2302392.
- Wharton S., Aronne L.J., Stefanski A., Alfaris N.F., Ciudin A., Yokote K., Halpern B., Shukla A.P., Zhou C., Macpherson L., Allen S.E., Ahmad N.N., Klise S.R. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. The New England Journal of Medicine. 2025;393(18):1796–1806. doi: 10.1056/NEJMoa2511774.
- Witkiewitz K., Anton R.F., O'Malley S.S., Hasin D.S., Silverman B.L., Aldridge A., Mann K. Reductions in world health organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: A review. JAMA Psychiatry. 2025 doi: 10.1001/jamapsychiatry.2025.2508.
- Xie Y., Choi T., Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine. 2025;31(3):951–962. doi: 10.1038/s41591-024-03412-w.
- Yammine L., Green C.E., Kosten T.R., de Dios C., Suchting R., Lane S.D., Verrico C.D., Schmitz J.M. Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: A pilot randomized controlled trial. Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco. 2021;23(10):1682–1690. doi: 10.1093/ntr/ntab066.
- Yammine L., Balderas J.C., Weaver M.F., Schmitz J.M. Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: A case series study. Journal of Addiction Medicine. 2023;17(4):481–484. doi: 10.1097/adm.0000000000001147.
- Yammine L., Grigson P.S., Schmitz J.M., Evans B.B., Hendershot C.S. The potential utility of glp-1 receptor agonist medications for addiction treatment: A narrative review of clinical and epidemiological evidence. Current Addiction Reports. 2025;12 doi: 10.1007/s40429-025-00657-4.
- Yuan Z., Li D., Feng P., Xue G., Ji C., Li G., Hölscher C. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease. European Journal of Pharmacology. 2017;812:82–90. doi: 10.1016/j.ejphar.2017.06.029.
Associated Data
Data Availability Statement
No data was used for the research described in the article.